Joseph joins Actineer with over three decades of leadership experience across the nuclear medicine, medical device and radiopharmaceutical industries, including at Ionetix, IMAGIN Molecular Corporation and Positron Corporation (OTC: POSC). He takes the helm as Actineer moves forward with the scaling of its Ac-225 manufacturing capabilities and preparations to supply the radiopharmaceutical industry with this valuable alpha emitter.
Before joining Actineer, Joseph held several senior executive roles in the radiopharmaceutical industry. Most recently, he served as VP of Clinical Operations at Ionetix Corporation, where he spearheaded their cardiac radiopharmaceutical clinical growth strategy, established new joint ventures with medical and private equity groups, contributed to their Targeted Alpha Therapy business segment, advised on regulatory product submissions, and managed their clinical trial. As President and CEO of IMAGIN Molecular Corporation, he led efforts to identify joint venture partners for cardiac and oncologic imaging. Prior to this, Joseph was President and Chairman of the Board at Positron Corporation, where he managed a joint venture with Neusoft, expanded the PET scanner business, acquired IS2 Medical Systems, and successfully led multiple funding rounds. Mr. Oliverio holds an MBA in Technology Management from the University of Phoenix, Arizona, and a Bachelor of Science in Nuclear Medicine Technology from SUNY University at Buffalo, New York.
